Changes of serum pentraxin-3 and hypersensitive CRP levels during pregnancy and their relationship with gestational diabetes mellitus

Autoři: Ning Yu aff001;  Hongyan Cui aff001;  Xu Chen aff001;  Ying Chang aff001
Působiště autorů: Department of Obstetrics, Tianjin Central Hospital of Obstetrics and Gynecology, Tianjin Key Laboratory of Human Development and Reproductive Regulation, Tianjin, China aff001
Vyšlo v časopise: PLoS ONE 14(11)
Kategorie: Research Article
doi: 10.1371/journal.pone.0224739



To investigate the changes of inflammatory factors pentraxin 3 (PTX3) and hypersensitive C-reactive protein (hs-CRP) during pregnancy and their relationship with gestational diabetes mellitus (GDM).


The nested case-control study method was used. Eighty non-obese single-pregnant women diagnosed with GDM were included into the case group (GDM, n = 80), together with another eighty pregnant women with normal glucose tolerance were matched in the same period and divided into the control group (CON, n = 80), for detecting multiple biochemical indicators in different pregnancy stages by ELISA.


The serum levels of PTX3 and hs-CRP in pregnant women increased with the increase of gestational age (p < 0.001, p < 0.001). The levels of PTX3 and hs-CRP in group GDM were significantly higher in the middle and late pregnancy stages than group CON (p < 0.01, p < 0.05; p < 0.05, p < 0.05). PTX3 was positively correlated with hs-CRP, body mass index (BMI), fasting plasma glucose (FPG), and homeostasis model assessment of insulin resistance (HOMAIR).


PTX3 and hs-CRP may be related to the pathogenesis of GDM, and they are significantly increased in the second trimester, which provides a new idea for early prevention and treatment of GDM and risk prediction of long-term cardiovascular diseases.

Klíčová slova:

Acute phase proteins – Blood – Cardiovascular diseases – Inflammation – Inflammatory diseases – Obesity – Pathogenesis – Pregnancy


1. Zhao B, Han X, Meng Q, Luo Q. Early second trimester maternal serum markers in the prediction of gestational diabetes mellitus. J Diabetes Investig. 2018; 9(4):967–974. doi: 10.1111/jdi.12798 29288571

2. Sellers EA, Dean HJ, Shafer LA, Martens PJ, Phillips-Beck W, Heaman M, et al. Exposure to Gestational Diabetes Mellitus: Impact on the Development of Early-Onset Type 2 Diabetes in Canadian First Nations and Non-First Nations Offspring. Diabetes Care. 2016; 39(12):2240–2246. doi: 10.2337/dc16-1148 27703026

3. Dongel I, Gokmen AA, Gonen I, Kaya S. Pentraxin-3 and inflammatory biomarkers related to posterolateral thoracotomy in Thoracic Surgery. Pak J Med Sci. 2019; 35(2):464–469. doi: 10.12669/pjms.35.2.181 31086534

4. Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest. 2006; 116(7):1793–1801. doi: 10.1172/JCI29069 16823477

5. Borish LC, Steinke JW. 2. Cytokines and chemokines. J Allergy ClinImmunol. 2003; 111(2 Suppl):460–475. doi: 10.1067/mai.2003.108 12592293

6. Agrawal A. CRP after 2004. Mol Immunol. 2005; 42(8):927–930. doi: 10.1016/j.molimm.2004.09.028 15829284

7. Tunc-Ata M, Turgut G, Mergen-Dalyanoglu M, Turgut S. Examination of levels pentraxin-3, interleukin-6, and C-reactive protein in rat model acute and chronic exercise. J Exerc Rehabil. 2017; 13(3):279–283. doi: 10.12965/jer.1734920.490 28702438

8. Hamed S, Behnes M, Pauly D, Lepiorz D, Barre M, Becher T, et al. Diagnostic value of Pentraxin-3 in patients with sepsis and septic shock in accordance with latest sepsis-3 definitions. BMC Infect Dis. 2017; 17(1):554. doi: 10.1186/s12879-017-2606-3 28793880

9. American Diabetes Association. Diabetes management guidelines. Diabetes Care. 2015; 38(Suppl 1):S1–S93.

10. Tang Qi, Li Xueqin, Song Peipei, Xu Lingzhong. Optimal cut-off values for the homeostasis model assessment of insulin resistance (HOMA-IR) and pre-diabetes screening: Developments in research and prospects for the future. Drug Discoveries & Therapeutics. 2015; 9(6):380–385. doi: 10.5582/ddt.2015.01207 26781921

11. Li X, Lu X. Study correlation between C-reactive protein and gestational Diabetes mellitus. Obstet Gynecol. 2007; 21:382–385.

12. Tosi F, Di Sarra D, Bonin C, Zambotti F, Dall’Alda M, Fiers T, et al. Plasma levels of pentraxin-3, an inflammatory protein involved in fertility, are reduced in women with polycystic ovary syndrome. Eur J Endocrinol. 2014; 170(3):401–409. doi: 10.1530/EJE-13-0761 24347428

13. Kianpour M, Saadatmand F, Nematbakhsh M, Fahami F. Relationship between C-reactive Protein and Screening Test Results of Gestational Diabetes in Pregnant Women Referred to Health Centers in Isfahan in 2013–2014. Iran J Nurs Midwifery Res. 2019; 24(5):360–364. doi: 10.4103/ijnmr.IJNMR_352_14 31516522

14. Lekva T, Michelsen AE, Bollerslev J, Norwitz ER, Aukrust P, Henriksen T, et al. Low circulating pentraxin 3 levels in pregnancy is associated with gestational diabetes and increased apoB/apoA ratio: a 5 year follow up study. Cardiovasc Diabetol. 2016; 15:23 doi: 10.1186/s12933-016-0345-1 26842615

15. Zhou Y, Qi C, Li S, Shao X, Mou S, Ni Z. Diabetic Nephropathy Can Be Treated with Calcium Dobesilate by Alleviating the Chronic Inflammatory State and Improving Endothelial Cell Function. Cell Physiol Biochem. 2018; 51(3):1119–1133. doi: 10.1159/000495491 30476916

16. Williams S, Cunningham E, Pories WJ. Surgical treatment of metabolic syndrome. Med Princ Pract. 2012; 21(4):301–309. doi: 10.1159/000334480 22222561

17. Yildirim M, Simavli SA, Uysal Derbent A, Kaygusuz I, Uysal S. Is There Any Relationship between Plasma Pentraxin 3 Levels and Gestational Diabetes Mellitus? Gynecol Obstet Invest. 2015; 80(4):223–227. doi: 10.1159/000373889 25722060

18. Todoric J, Handisurya A, Knapp B, Tura A, Pacini G, Kautzky-Willer A. Relationship of pentraxin 3 with insulin sensitivity in gestational diabetes. Eur J Clin Invest. 2013; 43(4):341–349. doi: 10.1111/eci.12051 23379644

19. Kansu-Celik H, Ozgu-Erdinc AS, Kisa B, Findik RB, Yilmaz C, Tasci Y. Prediction of gestational diabetes mellitus in the first trimester: comparison of maternal fetuin-A, N-terminal proatrial natriuretic peptide, high-sensitivity C-reactive protein, and fasting glucose levels. Arch Endocrinol Metab. 2019; 63(2):121–127. doi: 10.20945/2359-3997000000126 31038593

20. Dali-Youcef N, Mecili M, Ricci R, Andrès E. Metabolic inflammation: connecting obesity and insulin resistance. Ann Med. 2013; 45(3):242–253. doi: 10.3109/07853890.2012.705015 22834949

21. Ozgu-Erdinc AS, Yilmaz S, Yeral MI, Seckin KD, Erkaya S, Danisman AN. Prediction of gestational diabetes mellitus in the first trimester: comparison of C-reactive protein, fasting plasma glucose, insulin and insulin sensitivity indices. J Matern Fetal Neonatal Med. 2015; 28(16):1957–1962. doi: 10.3109/14767058.2014.973397 25283990

22. Grewal E, Kansara S, Kachhawa G, Ammini AC, Kriplani A, Aggarwal N, et al. Predict of gestanal diabetes mellitus at 24 to 28 weeks of gestational by using first-trimester insulin sensivity indices in Asian Indian subjects. Metabolism. 2012; 61(5):715–720. doi: 10.1016/j.metabol.2011.10.009 22146095

23. Rao M, Gao C, Xu L, Jiang L, Zhu J, Chen G, et al. Effect of Inulin-Type Carbohydrates on Insulin Resistance in Patients with Type 2 Diabetes and Obesity: A Systematic Review and Meta-Analysis. J Diabetes Res. 2019; 2019:5101423. doi: 10.1155/2019/5101423 31534973

Článek vyšel v časopise


2019 Číslo 11